Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
    • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.

    The EU Clinical Trials Register currently displays   38871   clinical trials with a EudraCT protocol, of which   6391   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    38,871 result(s) found. Displaying page 1,786 of 1,944.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    EudraCT Number: 2012-003058-10 Sponsor Protocol Number: IBCSG_42-12/BIG_2-12 Start Date*: 2013-04-03
    Sponsor Name:International Breast Cancer Study Group (IBCSG)
    Full Title: A randomized phase II study evaluating different schedules of nab-Paclitaxel in metastatic breast cancer
    Medical condition: Patients with histologically or cytologically confirmed HER2-negative metastatic (stage IV) breast cancer who have not received chemotherapy for metastatic breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Ongoing) SI (Ongoing) IE (Ongoing) IT (Completed) ES (Completed) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-005454-30 Sponsor Protocol Number: C-935788-049 Start Date*: 2014-11-28
    Sponsor Name:Rigel Pharmaceuticals, Inc.
    Full Title: A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura
    Medical condition: Persistent/Chronic Immune Thrombocytopenic Purpura
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004851 10067644 Immune-mediated thrombocytopenic purpura LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) IT (Completed) HU (Ongoing) CZ (Completed) AT (Completed) NL (Ongoing) DK (Completed) ES (Completed) PL (Completed) BG (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002625-31 Sponsor Protocol Number: 10041 Start Date*: 2006-12-11
    Sponsor Name:European Organisation for Research and Treatment of Cancer
    Full Title: Microarray In Node negative and 1 to 3 positive lymph node Disease may Avoid ChemoTherapy. A prospective, randomised study comparing the 70-gene expression signature with common clinical-pathologi...
    Medical condition: Lymph-node negative early breast cancer and breast cancer with 1 to 3 positive nodes
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults Gender: Female
    Trial protocol: BE (Completed) ES (Ongoing) SI (Completed) DE (Completed) GB (Completed) IT (Completed) PT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-004377-84 Sponsor Protocol Number: GO27834 Start Date*: 2013-04-11
    Sponsor Name:Genentech, Inc.
    Full Title: A randomized, open-label, multicenter, phase II trial evaluating the safety and activity of pinatuzumab vedotin (DCDT2980S) in combination with rituximab or polatuzumab vedotin (DCDS4501A) in combi...
    Medical condition: Follicular Non-Hodgkin’s Lymphoma (FL); Diffuse Large B-Cell Lymphoma (DLBCL)
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004864 10012857 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) refractory LLT
    20.0 100000004864 10012855 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) LLT
    20.1 100000004864 10012856 Diffuse large cell lymphoma (Diffuse large B-cell lymphoma) (Working Formulation) recurrent LLT
    20.0 100000004864 10067070 Follicular B-cell non-Hodgkin's lymphoma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) NL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-004977-23 Sponsor Protocol Number: DP312804 Start Date*: 2013-04-25
    Sponsor Name:SFJ LungCancer, Ltd.
    Full Title: ARCHER 1050: A RANDOMIZED, OPEN-LABEL, PHASE 3, EFFICACY AND SAFETY STUDY OF DACOMITINIB (PF 00299804) VERSUS GEFITINIB FOR THE FIRST LINE TREATMENT OF LOCALLY ADVANCED OR METASTATIC NON SMALL CELL...
    Medical condition: Non-Small Cell Lung Cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10029514 Non-small cell lung cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) IT (Completed) PL (Ongoing)
    Trial results: View results
    EudraCT Number: 2013-003629-27 Sponsor Protocol Number: 998HB303 Start Date*: 2014-05-20
    Sponsor Name:Bioverativ Therapeutics Inc.
    Full Title: An Open-Label, Multicenter Evaluation of the Safety and Efficacy of Recombinant Coagulation Factor IX Fc Fusion Protein (rFIXFc; BIIB029) in the Prevention and Treatment of Bleeding in Previously U...
    Medical condition: Hemophilia B (congenital coagulation factor IX [FIX] deficiency; Christmas disease) is an X-linked bleeding disorder that occurs predominantly in males, characterized by a deficiency of functional ...
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004850 10053754 Hemophilia B without inhibitors LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male
    Trial protocol: IE (Completed) GB (Completed) DE (Completed) SE (Completed) BE (Completed) ES (Completed) IT (Completed) DK (Completed) NL (Completed) PL (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2012-003505-10 Sponsor Protocol Number: ERIGE Start Date*: 2013-04-24
    Sponsor Name:GRUPPO ONCOLOGICO ITALIANO DI RICERCA
    Full Title: Phase II study of Eribulin in combination with Gemcitabine for the First-line Treatment of Patients with Locally Recurrent or Metastatic Triple Negative Breast Cancer. Protocol ERIGE.
    Medical condition: Locally recurrent or metastatic triple negative breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004864 10006197 Breast cancer NOS stage IV LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2020-000441-13 Sponsor Protocol Number: GR41986 Start Date*: 2020-08-27
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO CENTRAL RETINAL ...
    Medical condition: Macular edema secondary to Central Retinal or Hemiretinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Ongoing) PT (Ongoing) HU (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000440-63 Sponsor Protocol Number: GR41984 Start Date*: 2020-09-30
    Sponsor Name:F.Hoffmann La-Roche Ltd
    Full Title: A PHASE III, MULTICENTER, RANDOMIZED, DOUBLE-MASKED, ACTIVE COMPARATOR-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF FARICIMAB IN PATIENTS WITH MACULAR EDEMA SECONDARY TO BRANCH RETINAL ...
    Medical condition: Macular edema secondary to Branch Retinal Vein Occlusion
    Disease: Version SOC Term Classification Code Term Level
    20.0 10015919 - Eye disorders 10038907 Retinal vein occlusion PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Ongoing) DE (Ongoing) PT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-000442-34 Sponsor Protocol Number: NN1436-4477 Start Date*: 2020-09-09
    Sponsor Name:Novo Nordisk A/S
    Full Title: A 78-week trial comparing the effect and safety of once weekly insulin icodec and once daily insulin glargine 100 units/mL, both in combination with non-insulin anti-diabetic treatment, in insulin ...
    Medical condition: Diabetes Mellitus, Type 2
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004861 10045242 Type II diabetes mellitus LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) SK (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2018-000601-22 Sponsor Protocol Number: 331-201-00079 Start Date*: 2018-11-20
    Sponsor Name:Otsuka Pharmaceutical Development & Commercialization, Inc.
    Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Brexpiprazole as Adjunctive Therapy in the Maintenance Treatment of ...
    Medical condition: Major depressive disorder (MDD)
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004873 10025454 Major depressive disorder, recurrent episode LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Restarted) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-022338-10 Sponsor Protocol Number: H9H-MC-JBAK Start Date*: 2011-05-03
    Sponsor Name:Eli Lilly and Company
    Full Title: Phase 2 Study of LY2157299 in Patients with Hepatocellular Carcinoma
    Medical condition: Carcinoma, hepatocellular
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10019829 Hepatocellular carcinoma recurrent LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) IT (Ongoing)
    Trial results: View results
    EudraCT Number: 2009-013651-29 Sponsor Protocol Number: AGMT_CLL8/A Start Date*: 2010-01-13
    Sponsor Name:AGMT
    Full Title: MABTENANCE: International, Multicentre, Randomized Phase III Study of Rituximab as Maintenance Treatment versus Observation alone in Patients with Chronic Lymphocytic Leukemia
    Medical condition: Chronic Lymphocytic Leukemia
    Disease: Version SOC Term Classification Code Term Level
    19.0 100000004864 10009310 CLL LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SK (Completed) CZ (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2017-002325-38 Sponsor Protocol Number: A4250-008 Start Date*: Information not available in EudraCT
    Sponsor Name:Albireo AB
    Full Title: An Open-label Extension Study to Evaluate Long-term Efficacy and Safety of A4250 in Children with Progressive Familial Intrahepatic Cholestasis Types 1 and 2 (PEDFIC 2)
    Medical condition: Progressive Familial Intrahepatic Cholestasis Types 1 and 2
    Disease: Version SOC Term Classification Code Term Level
    20.0 10010331 - Congenital, familial and genetic disorders 10076033 Progressive familial intrahepatic cholestasis PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: DE (Ongoing) FR (Ongoing) SE (Ongoing) GB (GB - no longer in EU/EEA) NL (Ongoing) BE (Ongoing) ES (Ongoing) IT (Ongoing) PL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002518-11 Sponsor Protocol Number: 8835-004 Start Date*: 2014-01-16
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO ASSESS CARDIOVASCULAR OUTCOMES FOLLOWING TREATMENT WITH ERTUGLIFLOZIN (MK-8835/PF-04971729) IN SUBJECTS WITH TYPE 2 DIABETES ME...
    Medical condition: Type 2 Diabetes Mellitus
    Disease: Version SOC Term Classification Code Term Level
    20.0 10027433 - Metabolism and nutrition disorders 10067585 Type 2 diabetes mellitus PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) NL (Completed) GB (Completed) IT (Completed) ES (Completed) BG (Completed) PL (Completed) GR (Completed) HR (Ongoing) SK (Completed) LT (Completed) LV (Completed) CZ (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-005836-25 Sponsor Protocol Number: BAY73-4506/15967 Start Date*: 2012-06-12
    Sponsor Name:Bayer HealthCare AG
    Full Title: An open-label phase IIIb study of regorafenib in patients with metastatic colorectal cancer (CRC) who have progressed after standard therapy
    Medical condition: Colorectal neoplasms
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GB (Completed) IT (Completed) AT (Completed) NL (Completed) IE (Completed) FR (Completed) PT (Completed) FI (Completed) SE (Completed) GR (Completed) HU (Completed) PL (Completed) DK (Completed)
    Trial results: View results
    EudraCT Number: 2011-005328-17 Sponsor Protocol Number: MO28048 Start Date*: 2012-04-26
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A phase III prospective, two-cohort non-randomised, multi-centre, multinational, open label study to assess the safety of assisted- and self-administered subcutaneous trastuzumab as therapy in pati...
    Medical condition: HER2-positive primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10029104 Neoplasms benign, malignant and unspecified (incl cysts and polyps) SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IE (Completed) CZ (Completed) DE (Completed) ES (Ongoing) FR (Completed) HU (Completed) PT (Ongoing) GB (Completed) NO (Completed) IT (Completed) GR (Completed) LT (Completed) PL (Completed) SI (Completed) SK (Completed) FI (Completed) BG (Completed) NL (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2014-002108-25 Sponsor Protocol Number: CC-10004-BCT-002 Start Date*: 2015-06-17
    Sponsor Name:Amgen Inc.
    Full Title: A PHASE 3, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PARALLEL GROUP STUDY, FOLLOWED BY AN ACTIVE-TREATMENT PHASE TO EVALUATE THE EFFICACY AND SAFETY OF APREMILAST (CC-10004) IN THE...
    Medical condition: SUBJECTS WITH ACTIVE BEHÇET’S DISEASE
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004866 10004212 Behcet's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IT (Completed) GR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2015-001878-18 Sponsor Protocol Number: MK8962-043 Start Date*: 2017-07-19
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Multi-Center, Open Label, Single-Group Trial to Investigate the Efficacy and Safety of MK-8962 (corifollitropin alfa) in Combination with human Chorionic Gonadotropin (hCG) for Initiat...
    Medical condition: Treatment of adolescent males 14 to <18 years old with HH
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004860 10021012 Hypogonadotrophic hypogonadism LLT
    Population Age: Adolescents, Under 18 Gender: Male
    Trial protocol: IT (Completed) DK (Prematurely Ended) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-000374-37 Sponsor Protocol Number: 161505 Start Date*: 2016-10-28
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Long-Term Tolerability and Safety of Immune Globulin Infusion 10% (Human) with Recombinant Human Hyaluronidase (HYQVIA/HyQvia) for the Treatment of Chronic Inflammatory Demyelinating Polyradiculone...
    Medical condition: Chronic inflammatory demyelinating polyradiculoneuropathy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029205 - Nervous system disorders 10057645 Chronic inflammatory demyelinating polyradiculoneuropathy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Ongoing) DK (Completed) CZ (Ongoing) GB (GB - no longer in EU/EEA) ES (Ongoing) NO (Ongoing) GR (Ongoing) DE (Ongoing) PL (Ongoing) HR (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 1782  1783  1784  1785  1786  1787  1788  1789  1790  Next» Last»»
    Query did not match any studies.
    The status of studies in GB is no longer updated from 1.1.2021
    For the UK, as from 1.1.2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2021 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands     Legal notice
    EMA HMA